HIMS & HERS (HIMS) Q2 REPING 2025

shares Hims & Rels Health 9 % decreased in trading on Monday after the healthcare company announced a distance from results in the second quarter, which was lost, Wall Street, revenue.

Below is how the company did based on the intermediate analysts estimated by LSEG:

• Arrow’s profits: 17 cents were seized for 15 cents expected
• profit: 544.8 million dollars for $ 552 million expected

HIMS & HERS revenues increased by 73 % in the second quarter of 315.6 million dollars during the same period last year, according to a statement. Hims & Hers told a net income of $ 42.5 million, or 17 cents per share, compared to $ 13.3 million, or 6 cents per share, during the same period in the previous year.

For the third quarter, Hims & Hers said he expected to reach revenues between 570 million dollars and $ 590 million, while analysts expected $ 583 million. The company said that its modified profits before interest, taxes, consumption, fire, or profits before benefits, taxes, consumption and consumption will be between 60 million dollars and 70 million dollars. The survey analysts by Streetaccount had expected $ 77.1 million.

Hims & Hers has faced controversy in recent months because of its continued sale to the vehicle GLP-1SWhich are cheaper, unacceptable versions of scent diabetes and weight loss drugs. Completed drugs can be produced widely when the brand treatments are in lossBut the American Food and Drug Administration Declare In February, continuous display problems were solved.

Some healthcare companies, including Hims & Hers, continued to provide complex medicines. Legal for patients is to reach dedicated doses of judges in unique cases, as if they were allergic to one of the branded products, for example. Hims & Hers has He said Consumers may still be able to reach dedicated doses through its location if it is clinically applicable.

In June, the Hims & Hers shares decreased by more than 30 % after a Short -life cooperation with Novo Nordsk It collapsed. The pharmaceutical maker said that HIMS & HERS “failed to adhere to the law prohibiting the mass sales of complex drugs” under the “wrong appearance” of customization.

Hims & Hers told the average EBITDA of $ 82 million for the second quarter, an increase of 39.3 million dollars last year and more than $ 73 million expected by the street.

Hims & Hers will host their quarterly calls with investors at 5 pm Each time.

– Annika Kim Constantino of CNBC contributed to this report.